AUL
SLNO

AlphaGrep UK Ltd’s Soleno Therapeutics SLNO Stock Holding History

AlphaGrep UK Ltd’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,809
Closed -$547K – 922
2025
Q4 		$547K Buy
+11,809
New +$647K 0.18% 180

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

AlphaGrep UK Ltd's SLNO Position: Q1 2026 in Review

AlphaGrep UK Ltd sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 11,809 shares — an estimated $547K sold.

AlphaGrep UK Ltd first reported a position in SLNO in Q4 2025 and held it in 1 quarter. The position peaked at $547K in Q4 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • AlphaGrep UK Ltd reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaGrep UK Ltd sold 11,809 Soleno Therapeutics shares in Q1 2026, an estimated $547K.
  • AlphaGrep UK Ltd first reported a position in Soleno Therapeutics in Q4 2025 and held it in 1 quarter.
  • AlphaGrep UK Ltd's Soleno Therapeutics position peaked at $547K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.